Aurinia Pharmaceuticals Inc. (AUPH) NASDAQ
$5.01 0.01 (0.20%)
Market Cap: $724.53M
As of 03/28/24 04:00 PM EDT. Market closed.
Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ
$5.01
0.01 (0.20%)
Market Cap: $724.53M
As of 03/28/24 04:00 PM EDT. Market closed.
Add to Portfolio
aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, ... read more
aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Peter Greenleaf
Address
1203-4464 Markham St, British Columbia, Victoria, V8Z 7X8.
PRICE CHART FOR AURINIA PHARMACEUTICALS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$4.97
Previous Close
$5
Days Range
$4.86 - $5.01
52 week range
$4.85 - $12.43
Volume
1,375,006
Avg. Volume (30 days)
1,622,416
Market Cap
$724.53M
Dividend Yield
-
P/E
-
Shares Outstanding
144,617,762
Open
$4.97
Previous Close
$5
Days Range
$4.86 - $5.01
52 week range
$4.85 - $12.43
Volume
1,375,006
Avg. Volume (30 days)
1,622,416
Market Cap
$724.53M
Dividend Yield
-
P/E
-
Shares Outstanding
144,617,762
FINANCIAL STATEMENTS FOR AURINIA PHARMACEUTICALS INC
LOADING...
INSIDER TRANSACTIONS FOR AURINIA PHARMACEUTICALS INC
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Greenleaf Peter | Chief Executive Officer | Mar 06, 2024 | Sale | $5.60 | 126,981 | 711,094 | 1,522,114 | Mar 07, 2024, 04:46 PM |
Miller Joseph M | Chief Financial Officer | Mar 06, 2024 | Sale | $5.60 | 34,811 | 194,942 | 495,928 | Mar 07, 2024, 04:44 PM |
Donley Matthew Maxwell | EVP, Ops & Strategy | Mar 06, 2024 | Sale | $5.51 | 40,665 | 224,064 | 584,072 | Mar 07, 2024, 04:43 PM |
Habig Scott Michael | Chief Commercial Officer | Mar 06, 2024 | Sale | $5.60 | 17,777 | 99,551 | 474,587 | Mar 07, 2024, 04:42 PM |
Robertson Stephen P. | EVP, General Counsel | Mar 06, 2024 | Sale | $5.60 | 57,745 | 323,372 | 443,824 | Mar 07, 2024, 04:41 PM |
Knappertz Volker | EVP, Research and Development | Feb 27, 2024 | Sale | $6.10 | 4,930 | 30,073 | 319,128 | Feb 29, 2024, 04:11 PM |
Knappertz Volker | EVP, Research and Development | Feb 20, 2024 | Sale | $5.48 | 25,146 | 137,800 | 324,058 | Feb 22, 2024, 04:35 PM |
Habig Scott Michael | Chief Commercial Officer | Feb 20, 2024 | Sale | $5.48 | 15,867 | 86,951 | 492,364 | Feb 22, 2024, 04:33 PM |
Robertson Stephen P. | EVP, General Counsel | Mar 02, 2023 | Sale | $8.78 | 19,644 | 172,474 | 303,122 | Feb 22, 2024, 04:19 PM |
Miller Joseph M | Chief Financial Officer | Mar 02, 2023 | Sale | $8.78 | 11,398 | 100,074 | 331,112 | Feb 22, 2024, 04:17 PM |
Jayne David R.W. | Director | May 23, 2023 | Sale | $11.26 | 8,733 | 98,334 | 49,310 | May 23, 2023, 05:19 PM |
Hagan Joseph P | Director | May 19, 2023 | Sale | $10.58 | 272 | 2,878 | 11,961 | May 23, 2023, 05:18 PM |
Billen Daniel | Director | May 23, 2023 | Sale | $11.26 | 4,650 | 52,359 | 33,393 | May 23, 2023, 05:17 PM |
MacKay-Dunn R. Hector | Director | May 23, 2023 | Sale | $11.26 | 4,818 | 54,251 | 24,225 | May 23, 2023, 05:16 PM |
Leversage Jill | Director | May 23, 2023 | Sale | $11.26 | 4,815 | 54,217 | 18,528 | May 23, 2023, 05:14 PM |
MILNE GEORGE M JR | Director | Mar 02, 2023 | Buy | $8.91 | 20,000 | 178,284 | 70,000 | Mar 06, 2023, 04:29 PM |
Miller Joseph M | Chief Financial Officer | Mar 02, 2023 | Sale | $8.94 | 11,296 | 100,986 | 331,214 | Mar 06, 2023, 04:29 PM |
Robertson Stephen P. | EVP, General Counsel | Mar 02, 2023 | Sale | $8.94 | 19,402 | 173,454 | 303,364 | Mar 06, 2023, 04:29 PM |
Greenleaf Peter | Chief Executive Officer | Mar 02, 2023 | Sale | $8.94 | 32,750 | 292,785 | 982,968 | Mar 06, 2023, 04:27 PM |
Donley Matthew Maxwell | Ex VP, Internal Operations | Nov 21, 2022 | Buy | $4.66 | 10,000 | 46,600 | 27,927 | Nov 23, 2022, 04:04 PM |
Habig Scott Michael | Chief Commercial Officer | Nov 09, 2022 | Buy | $5.01 | 5,000 | 25,075 | 5,000 | Nov 14, 2022, 04:31 PM |
Martin Michael Robert | Chief Business Officer | Nov 07, 2022 | Buy | $5.16 | 30,000 | 154,800 | 89,512 | Nov 09, 2022, 04:05 PM |
Jayne David R.W. | Director | May 18, 2022 | Option Exercise | $3.62 | 10,000 | 36,200 | 40,000 | Jul 11, 2022, 06:16 AM |
MacKay-Dunn R. Hector | Director | Mar 09, 2022 | Buy | $11.00 | 5,000 | 54,985 | 11,000 | Mar 11, 2022, 04:05 PM |
MILNE GEORGE M JR | Director | Mar 04, 2022 | Buy | $10.82 | 5,000 | 54,100 | 50,000 | Mar 08, 2022, 04:06 PM |
Martin Michael Robert | Chief Business Officer | Mar 02, 2022 | Sale | $12.01 | 4,849 | 58,236 | 59,512 | Mar 04, 2022, 04:13 PM |
Donley Matthew Maxwell | Ex VP, Intern'l Operations | Mar 02, 2022 | Sale | $12.01 | 3,052 | 36,655 | 16,224 | Mar 04, 2022, 04:12 PM |
Miller Joseph M | Chief Financial Officer | Mar 02, 2022 | Sale | $12.01 | 3,060 | 36,751 | 6,610 | Mar 04, 2022, 04:12 PM |
Colao Massimilano | Chief Commercial Officer | Mar 02, 2022 | Sale | $12.01 | 3,205 | 38,492 | 13,495 | Mar 04, 2022, 04:11 PM |
Greenleaf Peter | Chief Executive Officer | Mar 02, 2022 | Sale | $12.01 | 9,068 | 108,907 | 32,967 | Mar 04, 2022, 04:11 PM |
Solomons Neil | Chief Medical Officer | Mar 02, 2022 | Sale | $12.01 | 4,846 | 58,200 | 90,953 | Mar 04, 2022, 04:10 PM |
Huizinga Robert Bindert | EVP of Research | Mar 02, 2022 | Sale | $12.01 | 4,849 | 58,236 | 69,379 | Mar 04, 2022, 04:10 PM |
Leversage Jill | Director | Dec 13, 2021 | Buy | $20.04 | 1,600 | 32,064 | 5,300 | Dec 15, 2021, 04:09 PM |
Martin Michael Robert | Chief Business Officer | Nov 11, 2021 | Option Exercise | $18.38 | 29,000 | 533,020 | 95,861 | Nov 12, 2021, 04:18 PM |
Martin Michael Robert | Chief Business Officer | Nov 10, 2021 | Sale | $31.14 | 60,000 | 1,868,500 | 76,861 | Nov 12, 2021, 04:18 PM |
Martin Michael Robert | Chief Business Officer | Nov 09, 2021 | Sale | $30.17 | 50,000 | 1,508,500 | 126,861 | Nov 12, 2021, 04:18 PM |
Martin Michael Robert | Chief Business Officer | Nov 11, 2021 | Sale | $29.01 | 40,000 | 1,160,280 | 66,861 | Nov 12, 2021, 04:18 PM |
Solomons Neil | Chief Medical Officer | Nov 11, 2021 | Option Exercise | $5.30 | 100,000 | 530,000 | 187,299 | Nov 12, 2021, 04:13 PM |
Solomons Neil | Chief Medical Officer | Nov 10, 2021 | Option Exercise | $5.83 | 100,000 | 583,200 | 187,299 | Nov 12, 2021, 04:13 PM |
Solomons Neil | Chief Medical Officer | Nov 09, 2021 | Sale | $30.17 | 50,000 | 1,508,500 | 87,299 | Nov 12, 2021, 04:13 PM |
Solomons Neil | Chief Medical Officer | Nov 11, 2021 | Sale | $28.89 | 100,000 | 2,889,000 | 87,299 | Nov 12, 2021, 04:13 PM |
Solomons Neil | Chief Medical Officer | Nov 10, 2021 | Sale | $31.11 | 100,000 | 3,110,800 | 97,299 | Nov 12, 2021, 04:13 PM |
Solomons Neil | Chief Medical Officer | Nov 01, 2021 | Option Exercise | $5.30 | 45,000 | 238,500 | 182,299 | Nov 03, 2021, 04:24 PM |
Solomons Neil | Chief Medical Officer | Nov 01, 2021 | Sale | $31.64 | 45,000 | 1,423,800 | 137,299 | Nov 03, 2021, 04:24 PM |
Martin Michael Robert | Chief Business Officer | Nov 01, 2021 | Option Exercise | $3.20 | 45,000 | 144,000 | 221,861 | Nov 03, 2021, 04:20 PM |
Martin Michael Robert | Chief Business Officer | Nov 01, 2021 | Sale | $31.64 | 45,000 | 1,423,800 | 176,861 | Nov 03, 2021, 04:20 PM |
Huizinga Robert Bindert | EVP of Research | Oct 25, 2021 | Option Exercise | $3.20 | 95,000 | 304,000 | 195,728 | Oct 26, 2021, 04:33 PM |
Huizinga Robert Bindert | EVP of Research | Oct 25, 2021 | Sale | $29.75 | 130,000 | 3,867,500 | 65,728 | Oct 26, 2021, 04:33 PM |
Huizinga Robert Bindert | EVP of Research | Sep 21, 2021 | Option Exercise | $2.86 | 27,136 | 77,715 | 133,228 | Sep 22, 2021, 04:53 PM |
Huizinga Robert Bindert | EVP of Research | Sep 21, 2021 | Sale | $23.99 | 32,500 | 779,533 | 106,092 | Sep 22, 2021, 04:53 PM |
Martin Michael Robert | Chief Business Officer | Sep 21, 2021 | Option Exercise | $7.40 | 87,500 | 647,750 | 264,361 | Sep 22, 2021, 04:31 PM |
Martin Michael Robert | Chief Business Officer | Sep 20, 2021 | Option Exercise | $5.30 | 28,500 | 151,050 | 205,361 | Sep 22, 2021, 04:31 PM |
Martin Michael Robert | Chief Business Officer | Sep 21, 2021 | Sale | $24.02 | 87,500 | 2,101,750 | 176,861 | Sep 22, 2021, 04:31 PM |
Martin Michael Robert | Chief Business Officer | Sep 20, 2021 | Sale | $21.65 | 28,500 | 616,975 | 192,861 | Sep 22, 2021, 04:31 PM |
Martin Michael Robert | Chief Business Officer | Sep 14, 2021 | Option Exercise | $5.30 | 44,000 | 233,200 | 220,861 | Sep 16, 2021, 05:01 PM |
Martin Michael Robert | Chief Business Officer | Sep 14, 2021 | Sale | $21.78 | 44,000 | 958,220 | 206,861 | Sep 16, 2021, 05:01 PM |
Martin Michael Robert | Chief Business Officer | Sep 14, 2021 | Option Exercise | $4.25 | 90,000 | 382,500 | 266,861 | Sep 14, 2021, 06:16 PM |
Martin Michael Robert | Chief Business Officer | Sep 13, 2021 | Option Exercise | $5.30 | 25,000 | 132,500 | 201,861 | Sep 14, 2021, 06:16 PM |
Martin Michael Robert | Chief Business Officer | Sep 14, 2021 | Sale | $21.19 | 90,000 | 1,907,217 | 176,861 | Sep 14, 2021, 06:16 PM |
Martin Michael Robert | Chief Business Officer | Sep 10, 2021 | Sale | $19.80 | 25,000 | 495,000 | 176,861 | Sep 14, 2021, 06:16 PM |
Huizinga Robert Bindert | EVP of Research | Sep 10, 2021 | Sale | $19.80 | 10,000 | 197,950 | 133,592 | Sep 14, 2021, 05:12 PM |
Huizinga Robert Bindert | EVP of Research | Sep 14, 2021 | Sale | $21.75 | 22,500 | 489,375 | 106,092 | Sep 14, 2021, 05:12 PM |
Solomons Neil | Chief Medical Officer | Sep 13, 2021 | Option Exercise | $3.20 | 150,000 | 480,000 | 287,299 | Sep 14, 2021, 05:11 PM |
Solomons Neil | Chief Medical Officer | Sep 10, 2021 | Sale | $19.84 | 150,000 | 2,976,000 | 137,299 | Sep 14, 2021, 05:11 PM |
Martin Michael Robert | Chief Business Officer | Sep 07, 2021 | Sale | $18.10 | 7,500 | 135,750 | 176,861 | Sep 08, 2021, 04:04 PM |
Huizinga Robert Bindert | EVP of Research | Sep 07, 2021 | Sale | $18.30 | 5,000 | 91,500 | 138,592 | Sep 08, 2021, 04:03 PM |
Martin Michael Robert | Chief Business Officer | Aug 26, 2021 | Sale | $17.81 | 22,500 | 400,725 | 184,361 | Aug 27, 2021, 04:09 PM |
Solomons Neil | Chief Medical Officer | Aug 25, 2021 | Sale | $15.85 | 5,000 | 79,250 | 137,299 | Aug 26, 2021, 04:15 PM |
Solomons Neil | Chief Medical Officer | Aug 09, 2021 | Sale | $16.03 | 45,000 | 721,350 | 142,299 | Aug 10, 2021, 04:11 PM |
Martin Michael Robert | Chief Business Officer | Aug 09, 2021 | Sale | $16.01 | 5,000 | 80,050 | 206,861 | Aug 10, 2021, 04:09 PM |
Martin Michael Robert | Chief Business Officer | Jul 28, 2021 | Sale | $13.86 | 5,000 | 69,300 | 211,861 | Jul 29, 2021, 04:09 PM |
Martin Michael Robert | Chief Business Officer | Jun 22, 2021 | Sale | $13.76 | 5,000 | 68,800 | 216,861 | Jun 23, 2021, 04:06 PM |
Donley Matthew Maxwell | Ex VP, Intern'l Operations | May 11, 2021 | Buy | $10.07 | 9,900 | 99,739 | 9,900 | May 12, 2021, 04:34 PM |
Greenleaf Peter | Chief Executive Officer | May 11, 2021 | Buy | $10.71 | 5,125 | 54,891 | 13,453 | May 12, 2021, 04:32 PM |
Solomons Neil | Chief Medical Officer | Mar 12, 2021 | Option Exercise | $3.02 | 40,000 | 120,800 | 227,299 | Mar 15, 2021, 04:36 PM |
Solomons Neil | Chief Medical Officer | Mar 12, 2021 | Sale | $13.49 | 40,000 | 539,600 | 187,299 | Mar 15, 2021, 04:36 PM |
MILNE GEORGE M JR | Director | Mar 05, 2021 | Buy | $13.00 | 5,000 | 65,000 | 45,000 | Mar 09, 2021, 04:25 PM |
Leversage Jill | Director | Jan 29, 2021 | Buy | $16.03 | 1,200 | 19,236 | 1,200 | Feb 02, 2021, 03:22 PM |
Leversage Jill | Director | Jan 29, 2021 | Buy | $16.03 | 400 | 6,412 | 400 | Feb 02, 2021, 03:22 PM |
Hayden Michael R | Director | Jan 29, 2021 | Option Exercise | $5.79 | 95,000 | 550,100 | 95,000 | Feb 02, 2021, 03:18 PM |
Robertson Stephen P. | EVP, General Counsel | Jan 28, 2021 | Buy | $16.14 | 900 | 14,526 | 2,720 | Jan 29, 2021, 12:24 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Owner | Relationship | Date | Value($) |
Greenleaf Peter | Chief Executive Officer | 03/06/2024 | 711,094 |
Miller Joseph M | Chief Financial Officer | 03/06/2024 | 194,942 |
Donley Matthew Maxwell | EVP, Ops & Strategy | 03/06/2024 | 224,064 |
Habig Scott Michael | Chief Commercial Officer | 03/06/2024 | 99,551 |
Robertson Stephen P. | EVP, General Counsel | 03/06/2024 | 323,372 |
Knappertz Volker | EVP, Research and Development | 02/27/2024 | 30,073 |
Knappertz Volker | EVP, Research and Development | 02/20/2024 | 137,800 |
Habig Scott Michael | Chief Commercial Officer | 02/20/2024 | 86,951 |
Robertson Stephen P. | EVP, General Counsel | 03/02/2023 | 172,474 |
Miller Joseph M | Chief Financial Officer | 03/02/2023 | 100,074 |
Jayne David R.W. | Director | 05/23/2023 | 98,334 |
Hagan Joseph P | Director | 05/19/2023 | 2,878 |
Billen Daniel | Director | 05/23/2023 | 52,359 |
MacKay-Dunn R. Hector | Director | 05/23/2023 | 54,251 |
Leversage Jill | Director | 05/23/2023 | 54,217 |
MILNE GEORGE M JR | Director | 03/02/2023 | 178,284 |
Miller Joseph M | Chief Financial Officer | 03/02/2023 | 100,986 |
Robertson Stephen P. | EVP, General Counsel | 03/02/2023 | 173,454 |
Greenleaf Peter | Chief Executive Officer | 03/02/2023 | 292,785 |
Donley Matthew Maxwell | Ex VP, Internal Operations | 11/21/2022 | 46,600 |
Habig Scott Michael | Chief Commercial Officer | 11/09/2022 | 25,075 |
Martin Michael Robert | Chief Business Officer | 11/07/2022 | 154,800 |
Jayne David R.W. | Director | 05/18/2022 | 36,200 |
MacKay-Dunn R. Hector | Director | 03/09/2022 | 54,985 |
MILNE GEORGE M JR | Director | 03/04/2022 | 54,100 |
Martin Michael Robert | Chief Business Officer | 03/02/2022 | 58,236 |
Donley Matthew Maxwell | Ex VP, Intern'l Operations | 03/02/2022 | 36,655 |
Miller Joseph M | Chief Financial Officer | 03/02/2022 | 36,751 |
Colao Massimilano | Chief Commercial Officer | 03/02/2022 | 38,492 |
Greenleaf Peter | Chief Executive Officer | 03/02/2022 | 108,907 |
Solomons Neil | Chief Medical Officer | 03/02/2022 | 58,200 |
Huizinga Robert Bindert | EVP of Research | 03/02/2022 | 58,236 |
Leversage Jill | Director | 12/13/2021 | 32,064 |
Martin Michael Robert | Chief Business Officer | 11/11/2021 | 533,020 |
Martin Michael Robert | Chief Business Officer | 11/10/2021 | 1,868,500 |
Martin Michael Robert | Chief Business Officer | 11/09/2021 | 1,508,500 |
Martin Michael Robert | Chief Business Officer | 11/11/2021 | 1,160,280 |
Solomons Neil | Chief Medical Officer | 11/11/2021 | 530,000 |
Solomons Neil | Chief Medical Officer | 11/10/2021 | 583,200 |
Solomons Neil | Chief Medical Officer | 11/09/2021 | 1,508,500 |
Solomons Neil | Chief Medical Officer | 11/11/2021 | 2,889,000 |
Solomons Neil | Chief Medical Officer | 11/10/2021 | 3,110,800 |
Solomons Neil | Chief Medical Officer | 11/01/2021 | 238,500 |
Solomons Neil | Chief Medical Officer | 11/01/2021 | 1,423,800 |
Martin Michael Robert | Chief Business Officer | 11/01/2021 | 144,000 |
Martin Michael Robert | Chief Business Officer | 11/01/2021 | 1,423,800 |
Huizinga Robert Bindert | EVP of Research | 10/25/2021 | 304,000 |
Huizinga Robert Bindert | EVP of Research | 10/25/2021 | 3,867,500 |
Huizinga Robert Bindert | EVP of Research | 09/21/2021 | 77,715 |
Huizinga Robert Bindert | EVP of Research | 09/21/2021 | 779,533 |
Martin Michael Robert | Chief Business Officer | 09/21/2021 | 647,750 |
Martin Michael Robert | Chief Business Officer | 09/20/2021 | 151,050 |
Martin Michael Robert | Chief Business Officer | 09/21/2021 | 2,101,750 |
Martin Michael Robert | Chief Business Officer | 09/20/2021 | 616,975 |
Martin Michael Robert | Chief Business Officer | 09/14/2021 | 233,200 |
Martin Michael Robert | Chief Business Officer | 09/14/2021 | 958,220 |
Martin Michael Robert | Chief Business Officer | 09/14/2021 | 382,500 |
Martin Michael Robert | Chief Business Officer | 09/13/2021 | 132,500 |
Martin Michael Robert | Chief Business Officer | 09/14/2021 | 1,907,217 |
Martin Michael Robert | Chief Business Officer | 09/10/2021 | 495,000 |
Huizinga Robert Bindert | EVP of Research | 09/10/2021 | 197,950 |
Huizinga Robert Bindert | EVP of Research | 09/14/2021 | 489,375 |
Solomons Neil | Chief Medical Officer | 09/13/2021 | 480,000 |
Solomons Neil | Chief Medical Officer | 09/10/2021 | 2,976,000 |
Martin Michael Robert | Chief Business Officer | 09/07/2021 | 135,750 |
Huizinga Robert Bindert | EVP of Research | 09/07/2021 | 91,500 |
Martin Michael Robert | Chief Business Officer | 08/26/2021 | 400,725 |
Solomons Neil | Chief Medical Officer | 08/25/2021 | 79,250 |
Solomons Neil | Chief Medical Officer | 08/09/2021 | 721,350 |
Martin Michael Robert | Chief Business Officer | 08/09/2021 | 80,050 |
Martin Michael Robert | Chief Business Officer | 07/28/2021 | 69,300 |
Martin Michael Robert | Chief Business Officer | 06/22/2021 | 68,800 |
Donley Matthew Maxwell | Ex VP, Intern'l Operations | 05/11/2021 | 99,739 |
Greenleaf Peter | Chief Executive Officer | 05/11/2021 | 54,891 |
Solomons Neil | Chief Medical Officer | 03/12/2021 | 120,800 |
Solomons Neil | Chief Medical Officer | 03/12/2021 | 539,600 |
MILNE GEORGE M JR | Director | 03/05/2021 | 65,000 |
Leversage Jill | Director | 01/29/2021 | 19,236 |
Leversage Jill | Director | 01/29/2021 | 6,412 |
Hayden Michael R | Director | 01/29/2021 | 550,100 |
Robertson Stephen P. | EVP, General Counsel | 01/28/2021 | 14,526 |
Load More Insider Transactions
FUNDS WITH A POSITION IN AURINIA PHARMACEUTICALS INC
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
BLACKROCK INC. | 8,921,049 | 0.00204% | 6.05% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 1,569,136 | 0.00148% | 5.47% | Other |
BALYASNY ASSET MANAGEMENT L.P. | 887,014 | 0.01% | 237.49% | Event Driven |
RENAISSANCE TECHNOLOGIES LLC | 135,000 | 0.00188% | -79.64% | Other |
D. E. SHAW & CO., INC. | 92,562 | 0.00073% | -74.08% | Other |
TIG ADVISORS, LLC | 268,750 | 0.09% | Exited | Event Driven |
ALPS ADVISORS INC | 100,524 | 0.00711% | -5% | Other |
AQR CAPITAL MANAGEMENT LLC | 21,435 | 0.00036% | 15.2% | Other |
HARVEST MANAGEMENT LLC | 15,000 | 0.06% | Exited | Event Driven |
TUDOR INVESTMENT CORP ET AL | 13,533 | 0.00105% | Exited | Event Driven, Other |
HARVEST MANAGEMENT LLC | 10,000 (Put) | 0.04% | Exited | Event Driven |
CHANGE IN SHARES OUTSTANDING FOR AURINIA PHARMACEUTICALS INC
STOCK BUYBACKS FOR AURINIA PHARMACEUTICALS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.59%
1Q
06/30/2023
0.64%
2Q
03/31/2023
0.73%
3Q
12/31/2022
1.07%
4Q
09/30/2022
1.29%
5Q
06/30/2022
1.39%
6Q
03/31/2022
1.42%
7Q
12/31/2021
7.86%
8Q
09/30/2021
11.87%
9Q
06/30/2021
12.06%
10Q
03/31/2021
12.78%
11Q
12/31/2020
13.43%
12Q
09/30/2020
17.43%
13Q
06/30/2020
27.64%
14Q
03/31/2020
28.05%
15Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR AURINIA PHARMACEUTICALS INC
LOADING...